Taking injected extended-release once-weekly exenatide for 84 weeks improved the glycemic control, weight and hypoglycemia risk in patients with type 2 diabetes, according to a study presented at the annual meeting of the American Diabetes Association. Exenatide-treated patients had 1.2% reduction in hemoglobin A1c levels and lost an average of 4.5 pounds, experts said.

Related Summaries